Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Omicron Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Atherosclerosis

Treatments: Drug: Ateronon

Study type: Interventional

Funder types: Industry

Identifiers

NCT01287182

OP2912011

Details and patient eligibility

About

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Enrollment: 100 patients

Sex: All

Ages: 35 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men and Women with demonstrated Coronary Disease
• AtheroAbzyme positive during screening process
• Elevated Total Cholesterol
• Willingness to take study nutritional supplement once a day for 3 months

Exclusion criteria

• Women who are pregnant, nursing or intend pregnancy during the period of treatment
• Known milk, soy or whey allergy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Ateronon

Active Comparator group

Treatment:

Drug: Ateronon